Rhumbline Advisers Decreases Stake in Pacira BioSciences, Inc. (NASDAQ:PCRX)

Rhumbline Advisers decreased its holdings in Pacira BioSciences, Inc. (NASDAQ:PCRX) by 4.5% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 154,073 shares of the company’s stock after selling 7,195 shares during the quarter. Rhumbline Advisers owned about 0.33% of Pacira BioSciences worth $2,903,000 as of its most recent filing with the SEC.

Other large investors have also recently bought and sold shares of the company. China Universal Asset Management Co. Ltd. grew its stake in shares of Pacira BioSciences by 10.3% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 9,790 shares of the company’s stock worth $184,000 after purchasing an additional 918 shares during the period. Caitlin John LLC boosted its holdings in Pacira BioSciences by 1,850.0% during the fourth quarter. Caitlin John LLC now owns 1,872 shares of the company’s stock worth $35,000 after buying an additional 1,776 shares in the last quarter. Nisa Investment Advisors LLC grew its position in Pacira BioSciences by 495.3% during the fourth quarter. Nisa Investment Advisors LLC now owns 3,304 shares of the company’s stock worth $62,000 after buying an additional 2,749 shares during the period. Quest Partners LLC grew its position in Pacira BioSciences by 137.6% during the third quarter. Quest Partners LLC now owns 9,410 shares of the company’s stock worth $142,000 after buying an additional 5,449 shares during the period. Finally, Virtus Investment Advisers Inc. purchased a new position in Pacira BioSciences in the third quarter valued at about $98,000. Hedge funds and other institutional investors own 99.73% of the company’s stock.

Wall Street Analyst Weigh In

Several equities research analysts have recently commented on PCRX shares. Needham & Company LLC boosted their price target on Pacira BioSciences from $30.00 to $32.00 and gave the stock a “buy” rating in a research note on Friday. Truist Financial upgraded Pacira BioSciences from a “sell” rating to a “hold” rating and boosted their target price for the stock from $8.00 to $25.00 in a research report on Thursday, January 30th. Royal Bank of Canada restated a “sector perform” rating and issued a $18.00 price target on shares of Pacira BioSciences in a research report on Tuesday, January 14th. Barclays lifted their price target on Pacira BioSciences from $17.00 to $24.00 and gave the stock an “overweight” rating in a research note on Friday. Finally, HC Wainwright raised their target price on shares of Pacira BioSciences from $57.00 to $70.00 and gave the company a “buy” rating in a report on Friday. One research analyst has rated the stock with a sell rating, four have assigned a hold rating and five have given a buy rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus price target of $27.22.

Pacira BioSciences Trading Down 5.2 %

Pacira BioSciences stock opened at $24.05 on Friday. The stock has a 50-day moving average price of $23.16 and a 200 day moving average price of $18.63. Pacira BioSciences, Inc. has a 52 week low of $11.16 and a 52 week high of $31.67. The stock has a market cap of $1.11 billion, a PE ratio of -11.85 and a beta of 0.80. The company has a current ratio of 2.25, a quick ratio of 1.89 and a debt-to-equity ratio of 0.51.

Pacira BioSciences Company Profile

Pacira Biosciences, Inc is a holding company, which engages in the provision of non-opioid pain management and regenerative health solutions to improve patients’ journeys along the neural pain pathway. Its products include EXPAREL, iovera, and DepoFoam. The company was founded in December 2006 and is headquartered in Tampa, FL.